| Literature DB >> 34614283 |
Jaeki Min1, Anand Mayasundari1, Fatemeh Keramatnia1, Barbara Jonchere2, Seung Wook Yang3, Jamie Jarusiewicz1, Marisa Actis1, Sourav Das1, Brandon Young1, Jake Slavish1, Lei Yang1, Yong Li1, Xiang Fu1, Shalandus H Garrett1, Mi-Kyung Yun4, Zhenmei Li4, Stanley Nithianantham1, Sergio Chai1, Taosheng Chen1, Anang Shelat1, Richard E Lee1, Gisele Nishiguchi1, Stephen W White4, Martine F Roussel2, Patrick Ryan Potts3, Marcus Fischer1,4, Zoran Rankovic1.
Abstract
Targeting cereblon (CRBN) is currently one of the most frequently reported proteolysis-targeting chimera (PROTAC) approaches, owing to favorable drug-like properties of CRBN ligands, immunomodulatory imide drugs (IMiDs). However, IMiDs are known to be inherently unstable, readily undergoing hydrolysis in body fluids. Here we show that IMiDs and IMiD-based PROTACs rapidly hydrolyze in commonly utilized cell media, which significantly affects their cell efficacy. We designed novel CRBN binders, phenyl glutarimide (PG) analogues, and showed that they retained affinity for CRBN with high ligand efficiency (LE >0.48) and displayed improved chemical stability. Our efforts led to the discovery of PG PROTAC 4 c (SJ995973), a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins that inhibited the viability of human acute myeloid leukemia MV4-11 cells at low picomolar concentrations (IC50 =3 pM; BRD4 DC50 =0.87 nM). These findings strongly support the utility of PG derivatives in the design of CRBN-directed PROTACs.Entities:
Keywords: IMiD; PG; PROTAC; cereblon; phenyl glutarimide
Mesh:
Substances:
Year: 2021 PMID: 34614283 PMCID: PMC8648984 DOI: 10.1002/anie.202108848
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336